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Objectives: Describe clinical and epidemiological differences and risk factors for death among Bloodstream Infections
(BSI) caused by Gram Negative (GN) and Gram Positive (GP) bacteria in the setting of solid organ transplantation.
Methods: We performed a retrospective analysis of medical records, which were evaluated patients undergoing solid
organ transplantation with BSI in the period from January 2000 to January 31, 2006 at Hospital São Paulo and Hospital do
Rim e Hipertensão (Universidade Federal de São Paulo, Brazil). It was also performed the analysis of risk factors for death.
Results: 195 patients were included in this study with a mean age of 43.3 (± 0.90) years, 114 (58.5 %) were male and, 81
(41.5 %) were female. 168 (86.2 %) were kidney transplants, 16 (8.2 %) kidney-pancreas, 5 (2.6 %) heart, 5 (2.6 %) liver and
1 (0.5 %) liver-kidney. The mean hospital stay was 34.2 (± 62.7) days. GN accounted for 147 (75.4 %) of the BSI episodes,
whereas 48 (24.6 %) were caused by GP. In the group with BSI by GN the most common site of infection was the urinary
tract in 68 (46.3 %) cases, and in the group with BSI by GP the most common was the primary source in
14 (29.1%) of the cases. The overall mortality of patients with BSI by GN was 19.7 % (29 cases) and by GP was 35.4 %
(17 cases) (p = 0.03). In multiple logistic regression analysis, the variables associated independently with death in patients
with BSI by GN were those who developed respiratory failure requiring mechanical ventilation Odds Ratio (OR) 13,2 95 %
Confidence Interval (CI) = 3.07–57.19 (p = 0.001), beyond those which had number equal to or greater than two
comorbidities OR 12.4 95 % CI = 1.90–80.35 (p = 0.008). In the population with BSI by GP only the respiratory failure
requiring mechanical ventilation OR 28.3 CI 95=2.53–317.1 (p = 0.007) was independently associated with death.
Conclusions: Patients with BSI showed the urinary source as the main site of infection. Death within 30 days occurred in
29 (19.7 %) patients with GN and 7 (35.4 %) patients with GP BSI (p = 0.03). Respiratory failure was a risk factor for death in
patients with BSI by GN and GP.Background
Transplantation is the treatment of choice for many pa-
tients with end-stage organ failure from a variety of
causes resulting in prolonged survival and better quality
of life for patients [1, 2].
Among the infectious complications of solid organ
transplantation, bacteremia is a major cause of mortality
[3]. Its incidence is estimated at 28 to 30 % in liver, 5 to
11 % in kidney, and 11 % in heart transplant recipients* Correspondence: zinsly@terra.com.br
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creativecommons.org/publicdomain/zero/1.0/[4, 5]. Aerobic gram-positive and gram-negative bacteria
are the most frequent agents, with variable frequencies
depending on the type of transplantation [6]. Mortality
rates range from 11–33 %, with higher rates occurring
among heart transplant patients [7].
Little is known about the differences between
bacteremia from gram-negative and gram-positive bac-
teria in the setting of solid organ transplantation and
their specific impact on mortality. This retrospective
study aims to evaluate these two issues.article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Table 1 Analysis of 195 isolated pathogens in solid organ
transplant recipients with bloodstream infection by gram
positive and gram negative bacteria
Pathogen Number Percent
Escherichia coli 60 36.9
Klebsiella pneumoniae 23 11.8
Pseudômonas aeruginosa 20 10.3
Enterobacter aerogenes 20 10.3
Staphylococcus aureus 16 8.2
Coagulase negative Staphylococci 15 7.7
Enterococcus spp 11 5.6
Acinetobacter baumannii 10 5.1
Serratia marcescens 5 2.6
Streptococcus pneumoniae 4 2.1
Stenotrophomonas maltophilia 3 1.5
Salmonella spp 2 1.0
Providencia spp 2 1.0
Burkholderia cepacea 1 0.5
Citrobacter spp 1 0.5
Listeria sp. 1 0.5
Streptococcus viridans 1 0.5
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The study was conducted at Hospital São Paulo and
Hospital do Rim e Hipertensão, both affiliated to the
Federal University of Sao Paulo, Brazil, and assessed a
retrospective cohort of solid organ transplant recipients
with bloodstream infections (BSIs) in the period from 1
January 2000 to 31 January 2006.
We evaluated only patients over 18 years of age with
monomicrobial BSI. In the case of more than one BSI
for the same patient, only the first episode was consid-
ered. Cases were selected form the microbioloy labora-
tory reports and CDC criteria was used to classify BSI
episodes, excluding false positive infections, and the
clinical and epidemiological data were collected from
their medical records.
The samples were processed with the BACTEC 9240
(Becton Dickinson, Maryland, USA) system. Biochemical
tests for identification and antimicrobial susceptibility
testing by disk diffusion were performed according to
standard procedures from the Clinical and Laboratory
Standards Institute [8].
The variables analyzed were gender, age, type of dialy-
sis, transfusion, immunosuppression (cyclosporine, aza-
thioprine, mycophenolate mofetil, tacrolimus, sirolimus,
prednisone, thymoglobulin or interleukin-2 blocker), liv-
ing or deceased donor, prior treatment for cytomegalo-
virus infection, acute rejection and its management,
Charlson index, length of hospital stay, mechanical ven-
tilation, shock, and the clinical outcome in the hospital.
Statistical analysis
To evaluate risk factors for mortality, we used a nested
case control studies comparing living and deceased pa-
tient after BSI. Univariate analysis of risk factors repre-
sented by nominal categorical variables was performed
using the chi-squared (X2) or Fisher’s exact test (FET) as
appropriate. For continuous variables with normal distri-
bution we used the Student t test and for non-normal
distribution we used the Mann–Whitney test. All signifi-
cance probabilities presented were two-tailed and a
p-value of less than 0.05 was considered statistically sig-
nificant. The odds ratio and its corresponding 95 % con-
fidence interval were analyzed. Variables found to be
significant by univariate analysis were then entered into
a multivariate model. All statistical analyses were per-
formed using the Statistical Package for the Social Sci-
ences software (version 16.0, SPSS Inc., Chicago, IL).
Results
We studied 195 patients with bloodstream infection
(BSI). Of these, 24.6 % (n = 48) had gram-positive (GP
BSI) and 75.4 % (n = 147) had gram-negative (GN BSI)
bloodstream infections (p = 0.94). Escherichia coli was
isolated in 36.9 % of the patients, and Klebsiellapneumoniae was the second most frequently isolated
agent, accounting for 11.8 % of BSI cases. Regarding
gram-positive agents, Staphylococcus aureus was the
most frequently found agent, isolated in 16 patients,
followed by coagulase-negative Staphylococci, found in
15 patients. Regarding the overall distribution of agents,
Staphylococcus aureus was the 5th (8.2 %) and
coagulase-negative Staphylococcus was the 6th (7.7 %)
most frequent agent (Table 1).
Most patients were males, 57.8 % of the patients with
GN BSI and 60.4 % of those with GP BSI (p = 0.75). The
mean and median ages of patients with GN BSI were re-
spectively 43.61 and 45.00 years, while in the GP BSI
group these were 42.31 and 40.50 years. A single trans-
plant was performed in 89.1 % of patients with GP BSI
and in 91.7 % of those with GN BSI (p = 0.61). Regarding
length of hospital stay, the mean and median values
were 35.4 days and 18.0 days, respectively, in the group
with GN BSI and 30.6 and 25.5 days in the GP BSI
group (Table 2).
Of the cases with GN BSI, 129 (87.8 %) were kidney
transplants, 12 (8.2 %) were pancreas-kidney, 1 (0.7 %)
was a heart transplant, 4 (2.7 %) were liver transplants
and 1 (0.7 %) was a liver-kidney transplant. Of the cases
with GP BSI, 39 (81.3 %) were kidney transplants, 4
(8.3 %) were kidney-pancreas transplants, 4 (8.3 %) were
heart transplants, and 1 (2.1 %) was a liver transplant
(Table 2).
Table 2 Univariate and multivariate analysis of risk factors for death among 147 solid organ transplant recipients with bloodstream
infection by gram negative bacteria
Variables Cases (147) Univariate Multivariate
Death Survival OR IC95 % p OR IC95 % p
N (%) N (%)
Male gender 20 (23.5) 65 (76.5) 1.81 0.76–4.30 0.21
ICU 11 (52.4) 10 (47.6) 6.6 2.45–17.78 <0.001 2.10 0.54–8.13 0.29
HAIs 15 (25.0) 45 (75.0) 1.74 0.77–3.94 0.21
Charlson≥ 3 15 (31.3) 33 (68.7) 2.76 1.20–6.34 0.03 0.68 0.17–2.74 0.59
Co-morb (liver disease) 5 (71.4) 2 (28.6) 12.1 2.21–65.99 0.003 1.45 0.13–15.58 0.76
Co-morb (cancer) 3 (75.0) 1 (25.0) 13.5 1.35–135.0 0.02 6.87 0.40–118.8 0.18
Co-morbidities (≥2) 8 (66.7) 4 (33.3) 10.9 3.00–39.34 <0.01 12.4 1.90–80.35 0.008
Deceased donor 20 (24.1) 63 (75.9) 1.94 0.82–4.61 0.15
Induction therapy 7 (22.6) 24 (77.4) 1.25 0.48–3.26 0.62
Acute rejection (AR) 21 (48.8) 22 (51.2) 1.66 0.54–4.24 0.31
AR-corticosteroids 6 (30.0) 14 (70.0) 1.94 0.67–5.58 0.23
OB-MMF 5 (11.6) 38 (88.4) 0.44 0.15–1.24 0.17
OB-Ciclosporine 16 (16.8) 79 (83.2) 0.61 0.27–1.39 0.28
Double-J 4 (9.8) 37 (90.2) 0.35 0.11–1.08 0.07
Pre tx dialysis 22 (17.1) 107 (82.9) 0.32 0.11–0.93 0.05 0.58 0.13–2.52 0.47
CMV 4 (20.0) 16 (80.0) 1.02 0.31–3.32 1.00
Shock 6 (46.2) 7 (53.8) 4.14 1.27–13.45 0.02 0.47 0.08–2.65 0.40
Respiratory failure 15 (62.5) 9 (37.5) 13.0 4.79–35.14 <0.001 13.2 3.07–57.19 0.001
Pre tx diabetes 2 (13.3) 13 (86.7) 0.60 0.13–2.81 0.74
Inadequate atb 12 (26.7) 33 (73.3) 1.82 0.78–4.21 0.18
ICU Intensive care unit, HAIs Health-acquired infections, OB onset of BSI, TX transplant, atb antimicrobial
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in 83 (56.5 %) of the patients with GN BSI and in 23
(47.9 %) of those with GP BSI (p = 0.30). Pre-transplant
dialysis was required by 129 (87.8 %) patients in the GN
BSI group and 41 (85.4 %) patients in the GP BSI group
(p = 0.067).
Considering both groups together, the most common
primary site of infection was the urinary tract, accounting
for 71 (36.4 %) cases. BSI ranked second, having been re-
ported as the primary infection in 37 (19.0 %) cases,
followed by gastrointestinal in 27 (13.8 %), pulmonary in
24 (12.3 %), other sites in 23 (11.8 %), surgical wound in-
fection in 7 (3.6 %) and skin infection in 6 (3.1 %) cases.
A double-J stent was used in 41 (27.9 %) cases with
GN BSI, while only one (2.1 %) case with GP BSI used
this type of device (p = 0.0002). A urinary fistula was
found in 4 (7.2 %) cases with GN BSI but in none of the
patients with GP BSI (p = 0.25).
Regarding the clinical features of the different
groups studied, 118 (80.3 %) patients with GN BSI
and 40 (83.3 %) with GP BSI had Charlson scores of
0–3 (p = 0.64). At the onset of the BSI, 21 (14.3 %)patients in the GN group and 7 (14.6 %) in the GP group
were hospitalized in the intensive care unit (p = 0.96).
Bacteremias were considered as healthcare-associated
infections (HAIs) in 60 (40.8 %) patients with GN and
19 (39.6 %) with GP (p = 0.88). Post-transplant dialysis
was necessary in 51 (34.7 %) patients in the GN group
and 11 (22.9 %) in the GP group (p = 0.13). Pre-
transplant diabetes mellitus was found in 15 (10.2 %) pa-
tients with GN BSI and in 6 (12.5 %) patients with GP
BSI (p = 0.66), whereas post-transplant diabetes mellitus
was found in 19 (12.9 %) patients with GN BSI and in 3
(6.3 %) patients with GN BSI (p = 0.20).
Of all patients with BSI, 26 (17.7 %) in the GN group
and 9 (18.8 %) in the GP group developed septic shock
(p = 0.87). Mechanical ventilation was required by 24
(16.3 %) patients with GN BSI and by 14 (29.2 %) pa-
tients with GP BSI (p = 0.052).
An indwelling urinary catheter was present in 36
(24.5 %) patients with GN BSI and 15 (31.2 %) patients
with GP BSI (p = 0.36). Antibiotic therapy was consid-
ered adequate in 102 (69.4 %) patients with GN BSI and
32 (66.8 %) patients with GP BSI (p = 0.72).
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tients with GN BSI and 7 (35.4 %) patients with GP
BSI (p = 0.03).
With regard to the immunosuppression regimen used
at the time of the BSI onset, prednisone was the drug
used in 143 (97.3 %) of the patients with GN and in 47
(97.9 %) of the patients with GP infections (p = 0.81).
With regard to cyclosporine, 95 (64.6 %) patients used
this immunosuppressant in the GN group versus 34
(70.8 %) in the GP group (p = 0.43). Azathioprine was
used in 75 (51.0 %) patients in the GN group and 24
(50.0 %) in the GP group (p = 0.90). mycophenolate mo-
fetil was used in 43 (29.3 %) patients in the first group
versus 9 (18.7 %) in the second (p = 0.15) tacrolimus was
used in 36 (24.5 %) patients with GN and 6 (12.5 %) with
GP (p = 0.08) and, finally, rapamycin was used in 4
(2.7 %) patients in the first group and 2 (4.2 %) in the
second (p = 0.61).
In the group with GN BSI, 31 (21.1 %) patients re-
ceived induction therapy versus 5 (10.4 %) in the GP
group (p = 0.09). The drug chosen for this purpose in 14
(9.5 %) cases in the first group and in 2 (4.2 %) cases in
the second group was thymoglobulin (p = 0.24). OKT3
was used in 4 (2.7 %) patients with GN BSI and in 2
(4.2 %) patients with GP BSI (p = 0.61), whereas the
interleukin-2 inhibitor was used in 5 (3.4 %) patients in
the first group and 1 (2.1 %) in the second (p = 0.64).
Acute rejection was diagnosed in 30 (20.4 %) of the pa-
tients with GN BSI and in 19 (39.6 %) patients with GP
BSI (p = 0.008). This acute rejection was treated with
methylprednisolone in 20 (13.6 %) patients in the first
group and 16 (37.5 %) in the second (p = 0.003). Thymo-
globulin was the preferred therapy in 4 (7.2 %) patients in
the GN group and 1 in the GP group (p = 0.81). OKT3
was used in 1 (0.7 %) patient in the GN group and 1
(2.1 %) in the GP group (p = 0.40). The interleukin-2 in-
hibitor was used in 4 (7.2 %) patients in the first group
and 1 (2.1 %) in the second group (p = 0.81).
CMV disease was diagnosed and treated with gancyclo-
vir prior to the BSI onset in 20 (13.6 %) patients with GN
infections and 3 (6.3 %) with GP infections (p = 0.17).
A univariate analysis was performed to identify risk
factors for death among transplant recipients with BSI,
comparing those who died with those who survived.
In the case of GN BSI, risk factors for death were
the stay in the ICU at the onset of bacteremia (OR
6.6 95 % CI 2.45–17.78), a Charlson index > 3 (OR
2.76 95 % CI 1:20–6.34) (p = 0.03), in addition to liver
disease (OR 12.1 95 % CI 2.21–65.99) (p = 0.003) and
malignancy (OR 5.13 95 % CI 1.35–135.0) (p = 0.02)
as comorbidities, as well as the presence of two or
more comorbidities (OR 9.10 95 % CI 3.00–9.34)
(p <0.01) compared with those with one comorbidity
or less altogether.Pre-transplant dialysis (OR 0.32 95 % CI 0.11–0.93)
(p = 0.05) was listed as a protective factor against
death, while shock at the onset of bacteremia (OR
4.14 95 % CI 1.27–13.45) (p = 0.02) and respiratory
failure (OR 13.0 95 % CI 4.79–35.14) (p <0.001) were
associated with higher mortality rates in this popula-
tion, based on the univariate analysis (Table 2).
On multiple logistic regression, the variables that
were independently associated with progression to
death were the development of respiratory failure
requiring mechanical ventilation (OR 2.13 95 % CI
3.07–57.19) (p <0.001) and ≥2 comorbidities (OR 12.4
95 % CI 1.90–80.35) (P = 0.008) (Table 2).
However, when we analyzed patients with GP BSI, we
observed that mortality was higher among those with
shock at the onset of bacteremia (OR 16.4 95 % CI
1.76–151.7) (p = 0.005) and respiratory failure (OR 34.8
95 % CI 5.91–204-8) (p < 0.001) based on the univariate
analysis. The use of cyclosporine at the onset of
bacteremia appeared to be a protective factor against
death (OR 0.17 95 % CI 0.04–0.66) (p = 0.02) (Table 3).
On multiple logistic regression in this population,
the variable that was independently associated with
death was the development of respiratory failure re-
quiring mechanical ventilation (OR 28.3 95 % CI
2.53–317.1) (p = 0.07) (Table 3).
Antimicrobial adequacy was not associated to mortal-
ity on the univariate analysis for both, GN BSI (OR 1.82
95 % CI 0.78–4.21) (p = 0.18), and GP BSI (OR 1.14 95 %
CI 0.33–4.00) (p = 1.00) (Tables 2 and 3).Discussion and conclusions
In our study, most of the isolates were gram-negative
(75.4 %), which may be related to the higher number of
kidney transplants in our series (86.2 %); this fact had
already been observed by other authors, since the urin-
ary tract is a major source of bacteremia caused by these
agents in this population [6]. At the same time, studies
concerning liver transplantation have also found a simi-
lar microbial distribution, which is assigned to the ab-
dominal source of these infections-the second most
common site in our study [9].
In a recent national multicenter study that covered al-
most three years of epidemiological surveillance of noso-
comial bloodstream infections, not only in transplant
recipients (the Brazilian SCOPE study), gram-negative
agents were also prominent and represented 58.5 % of
the isolates [10].
In some European studies that also included different
types of solid organ transplantations, gram-positive
agents have slightly surpassed gram-negatives. However,
most of these BSIs were related to the presence of a vas-
cular catheter [11, 12].
Table 3 Univariate and multivariate analysis of risk factors for death among 48 solid organ transplant recipients with bloodstream
infection by gram positive bacteria
Variable Cases (48) Univariate Multivariate
Death Survival OR IC95 % P OR IC95 % p
N (%) N (%)
Male gender 10 (34.5) 19 (65.5) 0.90 0.27–3.02 1.00
ICU 4 (57.1) 3 (42.9) 2.87 0.56–14.73 0.23
HAIs 10 (52.6) 9 (47.4) 3.49 1.01–12.05 0.06
Charlson≥ 3 5 (29.4) 12 (70.6) 0.66 0.18–2.35 0.75
Co-morb (liver disease) 0 0
Co-morb (cancer) 1 (50.0) 1 (50.0) 1.87 0.11–32.01 1.00
Co-morbidities (≥2) 1 (20.0) 4 (80.0) 0.42 0.04–4.11 0.64
Deceased donor 11 (47.8) 12 (52.2) 2.90 0.85–9.93 0.13
Induction therapy 17 (77.3) 5 (22.7) 0.60 0.47–0.77 0.15
Acute rejection (AR) 9 (47.4) 10 (52.6) 2.36 0.70–7.95 0.22
AR-corticosteroids 9 (50.0) 9 (50.0) 2.75 0.80–9.39 0.13
OB-MMF 1 (11.1) 8 (88.9) 0.18 0.02–1.58 0.13
OB-Ciclosporine 8 (23.5) 26 (76.5) 0.17 0.04–0.66 0.02 0.20 0.03–1.19 0.08
Double-J 1 (100.0) 0 (0) 0.34 0.23–0.51 0.35
Pre tx dialysis 16 (39.0) 25 (61.0) 3.84 0.42–34.94 0.40
CMV 1 (33.3) 2 (66.7) 0.91 0.08–10.79 1.00
Shock 6 (85.7) 1 (14.3) 16.4 1.76–151.7 0.005 1.24 0.06–27.37 0.89
Respiratory failure 12 (85.7) 2 (14.3) 34.8 5.91–204.8 <0.001 28.3 2.53–317.1 0.007
Pre tx diabetes 2 (33.3) 4 (66.7) 0.90 0.15–5.50 1.00
Inadequate atb 6 (37.5) 10 (62.5) 1.14 0.33–4.00 1.00
ICU Intensive care unit, HAIs Health-acquired infections, OB onset of BSI, TX transplant, atb antimicrobial
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primary site of infection, having been identified in
36.4 % of cases, which also supports the observation of a
greater incidence of gram-negative infections in the
study population. The presence of a double-J stent has
also been shown to be related to gram-negative BSIs.
Among patients with GP BSI, the rate of acute rejec-
tion (39.6 %) was higher than in the GN group (20.4 %)
(p = 0.008), which might help to explain the increased
use of methylprednisolone in the first group (37.5 % vs.
13.6 %, p = 0.003) and the higher mortality rate in the
GP group (35.4 %).
The overall mortality rate in the study population
(23.6 %) was very close to the rate observed in a popula-
tion that included only kidney transplant recipients,
from the same hospital and period (24.3 %) [13]. It is
worth noting that the above mentioned Brazilian SCOPE
study reports a mortality rate of 40 %, greater than that
found in our study probably because it covers only noso-
comial infections, where bacteria with reduced suscepti-
bility are more frequently found [10].
In our study, we observed higher mortality among pa-
tients with gram-positive BSI (35.4 %) vs. gram-negativeBSI (19.7 %) (p = 0.03). The mortality in the GN BSI
group was lower than that reported in some other
series (25–59 %) [6, 7, 14]. On the other hand, GP
BSI has been implicated as an independent risk factor
for death among liver transplant recipients, with re-
ported mortality rates of 28.5 % for infections caused
by S. aureus [15].
We found no association between antimicrobial ad-
equacy and mortality, as has been described in the litera-
ture [16, 17]. Most likely, the early adjustment of the
antimicrobial therapy based on partial results from posi-
tive blood cultures may have contributed to this fact.
The presence of more than two comorbidities was in-
dependently associated with death in patients with GN
BSI; the same was not observed in the GP group, where,
in turn, there were more episodes of acute rejection and
higher mortality rates, perhaps decreasing the relative
impact of comorbidities in this group.
The need for mechanical ventilation as a risk factor
for death, both in the GP and in the GN groups, was re-
ported in earlier studies [13, 18, 19] that assessed only
kidney or liver transplant recipients, while our series in-
cludes other solid organ transplants. This was the only
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in our study, based on the multivariate analysis, regard-
less of the type of bacteria involved in the episode; per-
haps this is a risk factor related to disease severity.
Another study that included only kidney transplant re-
cipients identified septic shock, chronic renal failure
requiring dialysis, comorbidities, and inadequate anti-
microbial therapy as factors associated with increased
mortality [20].
The limitations of our study are the retrospective ana-
lysis and the reliance on information based on clinical def-
initions and data from medical records, without direct
contact with the patients. This limitation was minimized
by the application of standards to ensure consistency in
the analysis of the patients’ medical records.
In this article we stress that GN and GP BSI in solid
organ transplant recipients have different and important
features. Understanding the characteristics and risk fac-
tors for death in the population of solid organ transplant
recipients with bloodstream infections may help to de-
sign strategies to decrease mortality rates associated with
this type of infection.
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